Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$397.48 0.22 (0.06%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 103.36(B)
Last Volume: 682,467 Avg Vol: 1,619,368
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 67,740 152,280 258,193 599,211
Total Sell Value $28,555,052 $61,805,647 $99,413,137 $200,212,570
Total People Sold 8 12 15 18
Total Sell Transactions 28 41 68 132
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 3258
  Page 10 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lee Yuchun Director   –       •      –    2023-01-27 4 OE $72.14 $103,088 D/D 1,429 3,304     -
   Lee Yuchun Director   –       •      –    2023-01-26 4 AS $315.42 $1,273,322 D/D (4,000) 1,875 3%     
   Lee Yuchun Director   –       •      –    2023-01-26 4 OE $72.14 $288,560 D/D 4,000 5,875     -
   Kewalramani Reshma CEO & President   •       •      –    2023-01-25 4 AS $315.05 $3,150,500 D/D (10,000) 89,598 6%     
   Lee Yuchun Director   –       •      –    2023-01-25 4 AS $312.80 $1,255,852 D/D (4,000) 1,875 6%     
   Lee Yuchun Director   –       •      –    2023-01-25 4 OE $72.14 $288,560 D/D 4,000 5,875     -
   Lee Yuchun Director   –       •      –    2023-01-24 4 AS $312.29 $1,250,753 D/D (4,000) 1,875 6%     
   Lee Yuchun Director   –       •      –    2023-01-24 4 OE $72.14 $288,560 D/D 4,000 5,875     -
   Lee Yuchun Director   –       •      –    2023-01-23 4 AS $312.02 $664,291 D/D (2,129) 1,875 4%     
   Lee Yuchun Director   –       •      –    2023-01-23 4 OE $72.14 $153,586 D/D 2,129 4,004     -
   Lee Yuchun Director   –       •      –    2023-01-18 4 AS $312.17 $137,979 D/D (442) 1,875 7%     
   Lee Yuchun Director   –       •      –    2023-01-18 4 OE $72.14 $31,886 D/D 442 2,317     -
   Lee Yuchun Director   –       •      –    2023-01-17 4 AS $312.03 $1,248,120 D/D (4,000) 1,875 7%     
   Lee Yuchun Director   –       •      –    2023-01-17 4 OE $72.14 $288,560 D/D 4,000 5,875     -
   Arbuckle Stuart A EVP, COO   •       –      –    2022-12-06 4 A $0.00 $0 D/D 12,753 58,031     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-11-15 4 AS $308.61 $10,493 D/D (34) 36,077 3%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-11-07 4 AS $299.72 $394,859 D/D (1,303) 36,077 -0%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-11-07 4 OE $187.53 $244,352 D/D 1,303 37,380     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-11-02 4 AS $310.10 $100,045 D/D (320) 38,104 -3%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-11-01 4 D $312.84 $240,261 D/D (768) 38,424     -
   Bhatia Sangeeta N. Director   –       •      –    2022-10-24 4 AS $310.00 $192,510 D/D (621) 4,040 -8%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-10-18 4 AS $300.02 $537,860 D/D (1,791) 39,192 -3%     
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2022-09-19 4 A $0.00 $0 D/D 5,294 5,294     -
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-15 4 AS $300.30 $6,738,991 D/D (22,173) 45,278 -6%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-08-15 4 OE $155.57 $1,022,250 D/D 6,571 67,451     -
  3258 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 10 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us